Laverdia® (verdinexor tablets)
Laverdia® combines a targeted mechanism with the convenience of oral administration that can be used immediately after diagnosis to treat canine lymphoma
- Laverdia® is the only FDA approved oral treatment for canine lymphoma1
- Laverdia® provides targeted treatment from the start that generally spares healthy cells2,3
- Straightforward dosing to support at home administration
- Demonstrated efficacy in dogs with B-cell and T-cell lymphoma2
| Pack size(s): | 2.5mg, 10mg, 50mg, 16 ct |
| Documents: | Package insert get_app SDS get_app |
Important safety information
As with all drugs, side effects may occur. For oral use in dogs only. Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia is a possible teratogen, can cause birth defects, and can affect female and male fertility. Laverdia can cause severe anorexia. Dogs should be carefully monitored for the most commonly reported adverse reactions including inappetence, vomiting, diarrhea, dehydration, weight loss, polyuria, polydipsia, elevated liver enzymes and thrombocytopenia, and supportive care should be provided as clinically indicated. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia or come into contact with the feces, urine, saliva, or vomit of Laverdia-treated dogs. Wear protective disposable chemotherapy resistant gloves when handling Laverdia to prevent direct contact with moistened, broken or crushed tablets and when handling feces, urine, saliva, or vomit or items that have come in contact with the treated dog during treatment and for 3 days after the last treatment. Refer to the prescribing information for complete details or visit www.dechra‐us.com.